

PipEracillin Tazobactam Versus mERoPENem for Treatment of Blood-stream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

NCT03671967

Status	RECRUITING
Phase	Phase 4
Sponsor	Rambam Health Care Campus
Enrollment	1,084 participants

Key Eligibility Criteria

Inclusion (5)

- Adults (age ≥ 18 years)
- New onset BSI due to *E. coli* or *Klebsiella* spp. in one or more blood cultures associated with evidence of infection.
- The microorganism will have to be non-susceptible to third generation cephalosporins (ceftriaxone and ceftazidime) and susceptible to both PTZ and meropenem (see microbiological methods).
- Both community and hospital-acquired bacteremias will be included.
- We will permit the inclusion of bacteremias due to *E. coli* or *Klebsiella* spp. with concomitant growth in blood of skin commensals considered as contaminants.

Exclusion (12)

- More than 72 hr. elapsed since initial blood culture taken, regardless of the time covering antibiotics were started (up to 72 hrs.).
- Polymicrobial bacteremia. Polymicrobial bacteremia will be defined as either growth of two or more different species of microorganisms in the same blood culture, or growth of different species in two or more separate blood cultures within the same episode.
- Patients with prior bacteremia or infection that have not completed antimicrobial therapy for the previous infectious episode.
- Patients with septic shock at the time of enrollment and randomization, defined as at least 2 measurements of systolic blood pressure < 90 mmHg and/or use of vasopressors (dopamine $> 15 \mu\text{g}/\text{kg}/\text{min}$, adrenalin $> 0.1 \mu\text{g}/\text{kg}/\text{min}$, noradrenalin $> 0.1 \mu\text{g}/\text{kg}/\text{min}$, vasopressin any dose) in the 12 hours prior to randomization. In the absence of the use of vasopressors, a systolic blood pressure < 90 would need to represent a deviation for the patient's known normal blood pressure.
- BSI due to specific infections known at the time of randomization:
... and 7 more (see full listing online)

Locations (14 total)

University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health, Calgary, Alberta, Canada
Surrey Memorial Hospital - Fraser Health Authority, Surrey, British Columbia, Canada
Eastern Health, St. John's, Newfoundland and Labrador, Canada
... and 11 more locations

<https://clinicaltrials.gov/study/NCT03671967>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).